Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

Journal:
Arthritis & Rheumatology
Published:
DOI:
10.1002/art.43428
Affiliations:
21
Authors:
21
Institutions Authors Share
Pfizer, United States of America (USA)
4.000000
0.19
Cincinnati Children's Hospital Medical Center (CCHMC), United States of America (USA)
3.000000
0.14
Hospital Pequeno Principe, Brazil
1.000000
0.05
Dell Children’s Medical Center, Seton Healthcare Family, United States of America (USA)
1.000000
0.05
Sydney Children's Hospitals Network, Australia
1.000000
0.05
The University of Utah (Utah), United States of America (USA)
1.000000
0.05
Istanbul Medeniyet University (IMU), Turkey
1.000000
0.05
Cohen Children's Medical Center, Northwell Health, United States of America (USA)
1.000000
0.05
Federal University of Rio de Janeiro (UFRJ), Brazil
1.000000
0.05
Ann and Robert H. Lurie Children's Hospital of Chicago, NU, United States of America (USA)
1.000000
0.05
Hacettepe University, Turkey
1.000000
0.05
São Paulo State University (UNESP), Brazil
1.000000
0.05
La Fe University Hospital, Spain
1.000000
0.05
University of Genova, Italy
1.000000
0.05
National Medical Research Center for Children's Health, Russia
0.500000
0.02
I.M. Sechenov First Moscow State Medical University (FMSMU), Russia
0.500000
0.02
University of Milano-Bicocca (UNIMIB), Italy
0.333333
0.02
Paediatric Rheumatology International Trials Organisation (PRINTO), Italy
0.333333
0.02
San Gerardo Hospital, Italy
0.333333
0.02